Cognition Therapeutics, Inc.

CGTX

US19243B1026

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-30 pm EDT			5-day change	1st Jan Change
1.91 ^USD	-1.04%		-4.50%	+3.24%

Apr. 29	Cognition Therapeutics, Inc. Completes Enrollment in Phase 2 SHIMmer Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies	CI
Apr. 12	Transcript : Cognition Therapeutics, Inc. - Special Call

Cognition Therapeutics, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023

March 11, 2024 at 04:12 pm EDT

Cognition Therapeutics, Inc. provided consolidated earnings guidance for the year ended December 31, 2023. For the year, the company expected net loss to be approximately $25.6 million.

Latest news about Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc. Completes Enrollment in Phase 2 SHIMmer Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies	Apr. 29	CI
Transcript : Cognition Therapeutics, Inc. - Special Call	Apr. 12
Transcript : Cognition Therapeutics, Inc., Q4 2023 Earnings Call, Mar 26, 2024	Mar. 26
Cognition Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Cognition Therapeutics Prices $11.5 Million Stock Offering	Mar. 12	MT
Cognition Therapeutics Starts Public Offering; Shares Decline	Mar. 11	MT
Cognition Therapeutics, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023	Mar. 11	CI
Cognition Therapeutics, Inc. Presents Analyses at AD/PD 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer?s Disease Studies	Mar. 06	CI
Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-To-Mod Moderate Alzheimer's Disease	Nov. 07	CI
Cognition Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Cognition Therapeutics, Inc. Appoints Quang Pham as Board Director	23-10-27	CI
Cognition Therapeutics, Inc. and Collaborators At Yale and ACTC Announce Oral Late-Breaking Presentation on the Start Study in Early Alzheimer?s Disease At CTAD	23-10-27	CI
Cognition Therapeutics, Inc. Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease At CTAD	23-10-24	CI
Top Premarket Decliners	23-10-06	MT
Top Premarket Decliners	23-08-30	MT
Ladenburg Thalmann Cuts Cognition Therapeutics' Price Target to $6 From $10, Keeps Buy Rating	23-08-14	MT
Transcript : Cognition Therapeutics, Inc., Q2 2023 Earnings Call, Aug 08, 2023	23-08-08
Cognition Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Companies in Alzheimer's race after US nod for Eisai/Biogen drug	23-07-07	RE
Cognition Therapeutics, Inc. and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 Start Study in Early Alzheimer's Disease	23-07-05	CI
Cognition Therapeutics Says Phase 2 Study of CT1812 Showed 'Positive Effects' in Alzheimer's Disease Patients	23-06-28	MT
Transcript : Cognition Therapeutics, Inc. - Special Call	23-06-28
Top Premarket Gainers	23-06-28	MT
Cognition Therapeutics, Inc. Announces Positive Topline Results for CT1812 Phase 2 Sequel Study for Mild-To-Moderate Alzheimerâ€™s Disease	23-06-28	CI
Cognition Therapeutics, Inc. Publishes Clinical Evidence that CT1812 Displaces Aß Oligomers from Binding to Neuronal Synapses in Alzheimer’s Disease	23-05-18	CI

Chart Cognition Therapeutics, Inc.

Duration

Period

More charts

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate CT1812 in clinical programs in Alzheimer's disease, dementia with Lewy bodies and dry age-related macular degeneration (dry AMD). Its lead product candidate, CT1812, is an investigational orally delivered, small molecule modulator that penetrates the blood-brain and blood-retina barriers and binds selectively to the sigma-2 receptor (S2R) complex; and through its modulation of S2R restores normal function of synapses, as well as critical cellular processes such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling, lipid membrane-bound protein trafficking and receptor stabilization at the cell surface. It is developing other product candidates in the area of synucleinopathies.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.91 USD

Average target price

6.667 USD

Spread / Average Target

+249.04%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
COGNITION THERAPEUTICS, INC.	+3.24%	76.47M
VERTEX PHARMACEUTICALS INCORPORATED	-3.46%	102B
REGENERON PHARMACEUTICALS, INC.	+1.41%	96.09B
ARGENX SE	+2.13%	22.28B
BIONTECH SE	-15.84%	21.4B
GENMAB A/S	-9.21%	18.14B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-14.65%	16.09B
NEUROCRINE BIOSCIENCES, INC.	+4.39%	13.83B
SAREPTA THERAPEUTICS, INC.	+31.35%	11.97B

Bio Therapeutic Drugs